news
Toujeo approved in the EU for the treatment of diabetes in adults
29 April 2015 | By Victoria White
The EC has granted marketing authorisation in Europe for Sanofi’s Toujeo for the treatment of type 1 and type 2 diabetes mellitus in adults...
List view / Grid view
Sanofi
news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
news
Sanofi announces top-line results for cardiovascular outcomes study of Lyxumia® (lixisenatide)
19 March 2015 | By Victoria White
Sanofi announce top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, comparing lixisenatide to placebo in adults with type 2 diabetes...
news
Sanofi receives FDA approval of once-daily basal insulin Toujeo®
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
news
Sanofi and MannKind announce Afrezza®, the only inhaled insulin, now available in the U.S.
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
news
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
news
Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol
19 November 2014 | By Sanofi / Regeneron Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…
news
Christopher A. Viehbacher removed as Sanofi’s Chief Executive Officer
29 October 2014 | By Sanofi
Sanofi's Board of Directors have decided unanimously to remove Christopher A. Viehbacher as Chief Executive Officer of Sanofi. As a consequence Christopher A. Viehbacher resigned as a director of Sanofi...
news
Sanofi and Regeneron present detailed positive results from four pivotal Alirocumab trials at ESC Congress 2014
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
news
Sanofi Pasteur announces publication of positive data for Fluzone® high-dose vaccine in The New England Journal of Medicine
14 August 2014 | By Sanofi
Sanofi Pasteur announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was more efficacious in preventing influenza...
news
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
12 August 2014 | By Sanofi
Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder...
news
Sanofi and Regeneron announce positive results from Phase 2b study of Dupilumab in patients with moderate-to-severe atopic dermatitis
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
news
FDA accepts Sanofi’s New Drug Application for basal insulin Toujeo®
8 July 2014 | By Sanofi
Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for Toujeo®...
news
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
news
Sanofi and Regeneron announce new, detailed data from positive sarilumab Phase 3 rheumatoid arthritis trial at EULAR
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
